| 1 |
30985942 | Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment. | 2019 May |
1 |
| 2 |
31090092 | Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron. | 2019 Nov |
3 |
| 3 |
26452722 | Prediction of Drug Clearance and Drug-Drug Interactions in Microscale Cultures of Human Hepatocytes. | 2016 Jan |
1 |
| 4 |
27440861 | The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine. | 2016 Oct |
4 |
| 5 |
25296725 | Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients. | 2015 Jan |
2 |
| 6 |
24880753 | Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine. | 2014 Aug |
3 |
| 7 |
23221858 | Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults. | 2013 Mar |
1 |
| 8 |
23486447 | Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. | 2013 May |
1 |
| 9 |
21976621 | Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. | 2012 Jan |
3 |
| 10 |
19884907 | The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. | 2010 Jun |
1 |
| 11 |
20840444 | Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials. | 2010 Oct |
3 |
| 12 |
19001559 | The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. | 2009 Feb |
2 |
| 13 |
19015855 | Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. | 2009 Jul |
2 |
| 14 |
19995332 | Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice. | 2009 Dec |
4 |
| 15 |
17667959 | Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. | 2008 Jun |
5 |
| 16 |
18310890 | Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain. | 2008 Mar |
3 |
| 17 |
18420781 | An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. | 2008 Jul |
3 |
| 18 |
18809731 | An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. | 2008 Dec |
1 |
| 19 |
18974610 | A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method. | 2008 |
2 |
| 20 |
16680561 | Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. | 2007 Feb |
1 |
| 21 |
15802801 | Different effects of desipramine on bufuralol 1''-hydroxylation by rat and human CYP2D enzymes. | 2005 Apr |
4 |
| 22 |
16338282 | Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. | 2005 Dec |
1 |
| 23 |
14610241 | Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. | 2004 Feb |
3 |
| 24 |
14730412 | Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics. | 2004 Feb |
1 |
| 25 |
15115913 | Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. | 2004 May |
3 |
| 26 |
16680870 | The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. | 2004 Apr |
1 |
| 27 |
12412819 | Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. | 2002 Nov |
3 |
| 28 |
11417443 | Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. | 2001 May |
3 |
| 29 |
10895986 | Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine. | 2000 Jun |
4 |
| 30 |
11037800 | Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial. | 2000 Oct |
2 |
| 31 |
9049581 | Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. | 1997 |
3 |
| 32 |
9205822 | Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. | 1997 Jun |
3 |
| 33 |
9220124 | Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly. | 1997 Jun |
2 |
| 34 |
9256169 | Specific binding of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl propyl) piperazine (GBR-12935), an inhibitor of the dopamine transporter, to human CYP2D6. | 1997 Jun 15 |
2 |
| 35 |
8848823 | Phenobarbital induces the 2-hydroxylation of desipramine. | 1996 Feb |
1 |
| 36 |
8938825 | No interaction between desipramine and bromperidol. | 1996 Oct |
1 |
| 37 |
7604141 | The effect of carbamazepine on the 2-hydroxylation of desipramine. | 1995 Feb |
1 |
| 38 |
8310712 | Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line. | 1993 Nov |
1 |
| 39 |
8335704 | Metabolism of imipramine in vitro by isozyme CYP2D6 expressed in a human cell line, and observations on metabolite stability. | 1993 Jun 2 |
2 |
| 40 |
8359181 | Polymorphic 2-hydroxylation of desipramine. A population and family study. | 1993 |
1 |
| 41 |
8513845 | Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. | 1993 |
2 |
| 42 |
1346258 | Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. | 1992 Jan |
1 |
| 43 |
1389951 | The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. | 1992 Sep |
1 |